Form 8-K - Current report:
SEC Accession No. 0001829126-26-000055
Filing Date
2026-01-06
Accepted
2026-01-06 07:30:47
Documents
17
Period of Report
2025-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalabio_8k.htm   iXBRL 8-K 34207
2 EXHIBIT 10.1 kalabio_ex10-1.htm EX-10.1 26759
3 EXHIBIT 10.2 kalabio_ex10-2.htm EX-10.2 42294
4 EXHIBIT 10.3 kalabio_ex10-3.htm EX-10.3 25672
5 EXHIBIT 10.4 kalabio_ex10-4.htm EX-10.4 19306
6 EXHIBIT 99.1 kalabio_ex99-1.htm EX-99.1 5272
  Complete submission text file 0001829126-26-000055.txt   345787

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE kala-20251230.xsd EX-101.SCH 2990
8 XBRL LABEL FILE kala-20251230_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE kala-20251230_pre.xml EX-101.PRE 22342
19 EXTRACTED XBRL INSTANCE DOCUMENT kalabio_8k_htm.xml XML 3091
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 26509411
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)